1 Symptom persistence and biomarkers in post-COVID-19/chronic fatigue

2

syndrome – results from a prospective observational cohort

A. F. Legler^{1,2,+}, L. Meyer-Arndt^{1,2,3,+}, L. Mödl⁴, C. Kedor⁵, H. Freitag⁵, E. Stein⁵, U.
Hoppmann^{1,2,3}, R. Rust^{1,2}, Frank Konietschke⁴, A. Thiel^{6,7}, F. Paul^{1,2,+}, C. Scheibenbogen^{5,+}, J.
Bellmann-Strobl^{1,2,+,*}

6

¹ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu
 Berlin and Berlin Institute of Health, Max Delbrück for Molecular Medicine, Experimental and Clinical Research
 Center, 13125 Berlin, Germany

² Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu
 Berlin and Berlin Institute of Health, NeuroCure Research Center, 10117 Berlin, Germany

12 ³ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu

Berlin and Berlin Institute of Health, Department for Neurology with Experimental Neurology, 10117 Berlin,
 Germany

⁴ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität
 zu Berlin and Institute of Biometry and Clinical Epidemiology, 10117 Berlin, Germany

⁵ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu
 Berlin and Berlin Institute of Health, Institute of Medical Immunology, 13353 Berlin, Germany

19 ⁶Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-20 Universität zu Berlin, and Berlin Institute of Health, Regenerative Immunology and Aging, BIH Center for

21 Regenerative Therapies, 13353 Berlin, Germany

⁷Si-M / "Der Simulierte Mensch" a science framework of Technische Universität Berlin and Charité Universitätsmedizin Berlin, 10117 Berlin, Germany

24

25

26 ⁺ Equal contribution

27 ^{*}Corresponding author

28 Contact information: Dr. Judith Bellmann-Strobl, email address judith.bellmann-29 strobl@charite.de

30 Abstract

Introduction: Post-COVID-19 syndrome (PCS) is characterized by a wide range of symptoms, predominantly fatigue and exertional intolerance. While disease courses during the first year post

infection have been repeatedly described, little is known about long-term health consequences.

Methods: We assessed symptom severity and various biomarkers at three time points post infection (3-8 months (mo), 9-16mo, 17-20mo) in 106 PCS patients with moderate to severe fatigue and exertional intolerance. A subset of patients fulfilled diagnostic criteria of myalgic encephalomyelitis/chronic fatigue syndrome (PCS-ME/CFS) based on the Canadian Consensus Criteria.

Results: While PCS-ME/CFS patients showed persisting symptom severity and disability up to 20mo
post infection, PCS patients reported an overall health improvement. Inflammatory biomarkers
equally decreased in both groups. Lower hand grip force at onset correlated with symptom
persistence especially in PCS-ME/CFS.

Discussion: Debilitating PCS may persist beyond 20mo post infection, particularly in patients fulfilling
 diagnostic criteria for ME/CFS.

45

46

47 Introduction

Post-COVID-19 syndrome (PCS) is worldwide recognized as sequela of coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)¹. There is a worrying number of patients with various persistent symptoms following mild or moderate COVID-19 mainly presenting as fatigue, exertion intolerance, headache, myalgia, neurological and cognitive deficits as well as orthostatic disturbances, which can severely impact the patients' quality of life.^{2–7} Reports estimate a proportion of 2%-10% of all COVID-19 patients to be impaired one year after infection.^{2,3,8}

55 More than two years into the SARS-CoV-2 pandemic, the WHO led the way to standardize the definition of PCS as part of the WHO International Classification of Diseases (ICD-10)⁴: The post-56 57 COVID condition occurs within three months after a probable SARS-CoV-2 Infection, lasts for at least 58 two months with an impact on everyday functioning and cannot be explained by alternative 59 diagnoses. Acknowledging the post-COVID condition was a crucial first step towards recognizing and 60 improving the health care situation of the patients affected. While the short- and medium-term 61 clinical presentations of PCS between 3 and 9 months after SARS-CoV-2 infection have been concisely 62 described,^{3,5,9} little is known to date about potential long-term health consequences that may prevail 63 beyond 12 months.

64 We reported previously on the first results of our ongoing prospective observational cohort study 65 initiated in August 2020 in order to characterize patients with persisting debilitating fatigue and

exertion intolerance following COVID-19.9 Our first analyses revealed that a subset of PCS patients 66 67 developed the full scope of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) 6 months 68 after initial infection⁹. ME/CFS is a complex multisystemic disease with an estimated pre-pandemic 69 worldwide prevalence of 0.2 to 0.8%. Approximately 3 million people were diagnosed with ME/CFS in Europe alone by 2020.^{10,11} It is characterized by pronounced fatigue and post exertional malaise 70 (PEM), cognitive impairment, orthostatic intolerance, pain and sleep disturbance while lacking 71 72 evidence of macroscopic organ damage. The key symptom of ME/CFS is an intolerance to mental and physical exertion, which triggers PEM.¹² Infections with various pathogens may cause ME/CFS such as 73 74 Epstein-Barr virus (EBV), enteroviruses, human herpes virus (HHV)-6, dengue viruses, intracellular 75 bacteria and SARS-CoV-1.¹³ The pathomechanism is still only partially elucidated: Infection-triggered 76 autoimmunity, viral mimicry, latent virus reactivation, and autonomous dysfunction including a dysregulation in ß2-adrenergic vasoconstriction are concepts currently debated.¹⁴ Specifically for 77 78 PCS-ME/CFS, studies have provided first evidence that autoantibodies to G protein-coupled receptors and endothelial dysfunction may play a role.¹⁵ Of interest, reactivation of EBV during 79 80 COVID-19 frequently occurs and is considered a risk factor for developing PCS. As infectious 81 mononucleosis caused by late primary EBV infection is a well-established trigger of ME/CFS, it is tempting to speculate that in a subset of PCS EBV may trigger the disease. ^{13,16–19}Here we present the 82 83 follow-up data up to 20 months after SARS-CoV-2 infection and identify predictive factors for the 84 disease course. We hypothesized that the subgroup of PCS-ME/CFS patients develops a chronic 85 condition with distinct clinical and paraclinical features.

86

87 Results

88 Cohort and symptom characteristics

We examined a total of 106 patients suffering from persistent moderate to severe fatigue and exertion intolerance 6 months post COVID-19 at up to two follow-up time points (9-16 months, and 17-20 months) after SARS-CoV-2 infection (**Supp. 1 Fig. 1**). 55 patients fulfilled the Canadian Consensus Criteria (CCC) for ME/CFS and are referred to as PCS-ME/CFS; the remaining 51 patients are referred to as PCS. For demographic characteristics see **Table 1**. Symptoms frequently reported by both post-COVID-19 and ME/CFS patients are shown in **Table 2** assessing symptom prevalence, severity, and evolution over time for both cohorts in detail.

96

97 Fatigue and PEM remain key symptoms in PCS-ME/CFS after 18 months

98 Fatigue and PEM are among the key symptoms of PCS and indispensable for the diagnoses of 99 ME/CFS. Patients diagnosed with PCS-ME/CFS were significantly more affected by fatigue than PCS 100 patients over the entire study period. At baseline, PCS patients presented on average lower Chalder 101 Fatigue Scale (CFQ) scores than PCS-ME/CFS patients with 33 % of PCS and 55% of PCS-ME/CFS 102 reporting severe (≥ 28 points) fatigue (Fig. 1a and Supp. 1 Table 1). While CFQ scores remained on a 103 similarly high level in the PCS-ME/CFS cohort, they significantly decreased in PCS patients. At follow-104 up 2, only 3% of PCS but 46 % of PCS-ME/CFS patients still reported CFQ scores ≥ 28 points. The 105 course of symptom severity was similar for the Chalder sub-score of physical fatigue (Fig. 1b), the 106 Short Form (36) (SF-36) Health Questionnaire fatigue score (Fig. 1c) and the fatigue score of the 107 quantitative CCC (qCCC; Supp. 1 Fig. 2a). Mental fatigue slightly improved also in PCS-ME/CFS over 108 time (Fig. 1d).

PEM duration, severity and frequency were all significantly higher in PCS-ME/CFS compared to PCS patients at baseline and remained at a higher level up to follow-up 2 (**Fig. 2a-c**). However, neither of the two cohorts experienced a reduction of PEM duration over time but an improvement in PEM frequency and severity. Remarkably, in the PCS-ME/CFS cohort, PEM duration decreased below 10 hours in 7 individuals (17%) at follow-up 2 (thus no longer fulfilling CCC) (**Fig. 2a**). Five of these seven individuals showed an equally strong improvement in PEM severity and frequency.

115

116 Reduced functional disability in both cohorts over time

117 At baseline, both PCS and PCS-ME/CFS patients had a low median Bell disability score of 40 with 4/55 118 PCS-ME/CFS patients and 1/51 PCS patients reporting an inability to leave the house (Bell score 20; 119 Fig. 3a), 53 of 55 PCS-ME/CFS and 43 of 51 PCS reported that they are unable to work full- or part-120 time (Bell score < 70/100). At follow-up 2, Bell score remained at 40 in PCS-ME/CFS but increased to 121 60 in PCS with only 12% of PCS-ME/CFS (5/41) but 43% of PCS patients reporting a Bell score > 70. 122 Patient reports on performance capacity as assessed with the gCCC confirmed this course (Supp. 1 123 Fig. 2b). Again, the seven PCS-ME/CFS patients who reported less PEM duration over time also 124 considerably improved on the Bell score (Fig. 3a).

Various sub-scores of the SF-36 were lower in PCS-ME/CFS compared to PCS at baseline (**Supp. 1 Table 1**) and group differences increased over time, mainly due to higher scores in PCS at both follow-ups (**Fig. 3a-d**). Specifically, perception of physical functioning (SF-36) was more reduced in PCS-ME/CFS compared to PCS patients from the beginning with only minor improvement at followup 2 in PCS-ME/CFS (median 45-50) and moderate in PCS (median 55-70) (**Fig. 3c**). Despite group differences in fatigue (**Fig. 1a-c**), PEM (**Fig. 2a-c**) and (perception of) functional disability (**Fig. 3a, c**),

131 overall health perception as measured by the SF-36 was equally reduced to levels below 50% in both

cohorts at baseline (**Fig. 3d**). Taken together, while PCS reported improved health perception up to

133 follow-up 2, PCS-ME/CFS patients stagnated at their initial level.

134

135 Emotional well-being improves in PCS patients only

136 Perception of emotional well-being as measured by the SF-36 was equally reduced by 50% in both 137 cohorts at baseline (Fig. 4a). Further, no differences in the Patient Health Questionnaire 9 (PHQ9), 138 which is used as a screening tool for affective disorders, was found at baseline (Fig. 4b). Seven 139 patients (6 PCS-ME/CFS; 1 PCS) reached more than 20 points on the PHQ9 score at baseline, which 140 suggests a PCS-associated affective burden. However, the PHQ9 includes symptoms of fatigue, 141 cognition and sleep and thus has a low specificity for depression in PCS and ME/CFS. Impairment 142 according to the PHQ9 improved in PCS patients from baseline to follow-up 2 but remained largely 143 unchanged in the PCS-ME/CFS cohort (Fig. 4a and b). Together, these scores indicate a considerable 144 emotional burden due to illness, which over time improves in PCS patients while PCS-ME/CFS 145 patients remain severely impaired.

146

147 PCS-ME/CFS remain more severely affected by pain than PCS

148 According to the SF-36 pain score, PCS-ME/CFS patients were more affected by pain than PCS 149 patients at all time points and improved in the PCS cohort from baseline to follow-up 2 while there 150 was just a minor improvement among PCS-ME/CFS patients (Fig. 5a). In detail, muscle pain (qCCC) 151 was reported by 85% of PCS-ME/CFS patients and 78% of PCS patients at baseline while joint pain 152 (qCCC) was reported by 64% of PCS-ME/CFS patients and 69% of PCS patients (Table 2, Supp. 1 Fig. 153 **2c and d**). None of these symptoms improved significantly over time in either of the two cohorts: 154 Both patient groups reported joint and muscle pain with a severity of more than 5/10 up to follow-up 155 2. Headaches were mentioned by 82% PCS and 93% PCS-ME/CFS patients at baseline with a 156 decreasing severity over time in both cohorts (Supp. 1 Fig. 2e).

157

158 Prevalence of neurological symptoms remains at a high level in both cohorts

At baseline, the prevalence of cognitive symptoms such as concentration (**Supp. 1 Fig. 2f**) and memory/wordfinding difficulties (**Table 2**), mental fatigue (**Supp. 1 Fig. 2g**), and difficulties while reading (**Table 2**) was comparable in both cohorts. Assessing symptom evolution over time, overall cognitive impairment as summarized in the qCCC (**Supp. 1 Fig. 2h**) ameliorated solely in PCS patients.

Hypersensitivities to noise, light and temperature, which are characteristic symptoms in ME/CFS were more frequent in PC-ME/CFS (**Table 2**) and all of them were more pronounced in PCS-ME/CFS at second follow-up. High median symptom severity scores at follow-up 2 indicated a continuous burden from neurological impairment despite overall improvement (**Table 2**).

167

168

169 Clinical signs of ongoing inflammation persist in PCS-ME/CFS patients

Patients suffering from postinfectious fatigue syndromes often state persisting flu-like symptoms,
painful lymph nodes and a sore throat, which can be signs of ongoing inflammation. These symptoms
were here summed up as qCCC immune score (Supp. 1 Fig. 2i), which was equally elevated in both
cohorts at baseline. However, symptoms significantly decreased in PCS patients but persisted in PCSME/CFS patients (Supp. 1 Fig. 2i).

175

176 Regression of autonomic dysfunctions in both PCS and PCS-ME/CFS patients

177 Autonomic dysfunction is a common feature of postinfectious fatigue syndromes. At baseline, PCS 178 and PCS-ME/CFS patients showed comparable signs of autonomic dysfunction reflected by a 179 Composite Autonomic Symptom Score 31 (COMPASS 31) overall score indicative of moderate to 180 severe complaints. Despite an improvement of this overall score over time in both cohorts, PCS-181 ME/CFS patients were more affected at second follow-up than PCS (Fig. 5b and Supp. 1 Tab. 1). 182 Gastrointestinal complains only improved in PCS patients with an almost unchanged level of 183 impairment in PCS-ME/CFS at follow-up (Fig. 5c and Supp. 1 Fig. 2j). On a similar note, PCS-ME/CFS 184 patients continued to suffer from more severe sleep disturbances compared to PCS (qCCC; Supp. 1 185 Fig. 2k).

186 To further characterize autonomic dysfunction in our patients and investigate potential clinical 187 implications, we measured the adaption of blood pressure and pulse to postural change. At baseline, 188 7% (5/42) of PCS and 11% (5/44) of PCS-ME/CFS patients showed signs of postural tachycardia 189 syndrome (POTS) and 4% (2/42) of PCS and 6% (3/44) of PCS-ME/CFS showed signs of orthostatic 190 hypotension (OH). Up to follow-up 2, none of the PCS patients continued to show signs of POTS or 191 OH (but two patients showed newly emerged symptoms of OH or POTS at follow-up 1). In contrary, 192 6% (3/44) of PCS-ME/CFS presented POTS symptoms also at follow-up 2 suggesting a persistent 193 autonomic dysfunction in this cohort (one patient showed new signs of OH).

194

195 Persistent diminished HGS but improvement of muscle fatiguability over time

196 Hand grip strength (HGS), a reliable parameter to quantify frailty and mortality, was evaluated in in 197 two consecutive sessions at baseline (for female patients only to avoid gender bias and due to an 198 insufficient number of male patients, n=35 PCS, n=49 PCS-ME/CFS) and follow-up 1 (n=25 PCS, n=37 199 PCS-ME/CFS; Fig. 6) and results were compared to age-dependent reference values as reported by Jäkel et al.²⁹ We found no significant differences in mean (fmean) and maximum force (fmax) 200 201 between PCS and PCS-ME/CFS and no changes in HGS over time in either cohort. A remarkable 202 number of PCS (63%) and PCS-ME/CFS patients (67%) showed measurements below their respective 203 cut-offs, i.e., for mean force in the second session (fmean2) at baseline and follow-up 1 (PCS 40%; 204 PCS/ME/FCS 67 %; Fig. 6a and b).

The fatigue ratio (fmax/fmean) was determined for each session as a correlate for muscle fatigability with higher values indicating a stronger decline in force (**Fig. 6e and f**).²⁹ PCS-ME/CFS patients showed higher fatigue ratios at baseline (session 2) and at follow-up (session 1) than PCS patients. The fatigue ratio decreased over time in both cohorts. No changes over time (or group differences) were found for the recovery ratio, which serves as marker for muscle strength recovery after an hour (**Fig. 6g**).²⁹

211

212 Reduction of inflammation markers over time in both cohorts

213 We investigated a range of biomarkers linked to postinfectious fatigue in a subset of patients (PCS 214 n=35; PCS-ME/CFS n=31). Previous studies have found that the proinflammatory and neutrophil-215 recruiting interleukin 8 (IL-8, CXCL8), antinuclear antibodies (ANA) and ferritin were associated with the post-COVID condition.²⁰⁻²² Among these patients, IL-8, which was determined after erythrocyte 216 217 lysis to reflect its level of production for a duration of up to 3 months, was equally elevated in almost 218 half of both patient cohorts at baseline.²³ Over time, IL-8 levels decreased significantly in both groups 219 (Fig. 7a). Consistently, ferritin, another inflammatory marker, was equally increased in almost a third of all patients at baseline, but again decreased in both cohorts until follow-up 2 (Fig. 7b). Antinuclear 220 221 antibodies (ANA) were detected in 25% (8/32) of PCS patients and 26% (8/30) PCS-ME/CFS patients 222 at baseline without significant changes over time (Fig. 7c). Furthermore, 35% of all patients were deficient of serum phosphate (PO4) at baseline, which is associated with increased mortality in 223 COVID-19.²⁴ Up to follow-up 1, this deficiency receded in most PCS patients while persisting in PCS-224 225 ME/CFS (Fig. 7e).

226

Initial hand grip strength is associated with symptom burden at follow-up in PCS-ME/CFS

229 As disease courses and outcomes vary between individual patients, we aimed at identifying an 230 objective marker, which could be used to estimate disease prognosis. We found HGS to be diminished in PCS-ME/CFS and to be associated with disease severity.²⁵ In line with this, we observed 231 232 HGS baseline measurements at baseline to strongly correlate with symptom burden in PCS-ME/CFS 233 patients at follow-up 1: Low HGS mean and maximum force at baseline correlated with increased 234 fatigue (CFQ), PEM, functional disability, pain, sleep disturbance and emotional impairment at follow-235 up 1. Consistently, a high HGS fatigue ratio indicating faster fatiguability at baseline correlated with 236 increased fatigue (CFQ) and functional disability at follow-up 1, and low HGS recovery ratios at 237 baseline with increased fatigue (CFQ) and disability at follow-up 2 (Fig. 8a). In PCS patients, we found 238 fewer and weaker correlations of some HGS parameters at baseline with symptom outcomes at 239 follow-up (Fig. 8b).

240 Next, we evaluated potential associations between biomarkers at baseline and persisting disease 241 burden. In the PCS-ME/CFS cohort, high IL-8 levels at baseline were associated with decreased social 242 functioning at follow-up 1 and high PEM severity at follow-up 2. High ferritin levels correlated with 243 increased cognitive impairment at both follow-ups as well as with poor health perception and more 244 limitation due to physical health at follow-up 1. Further, elevated ANA levels correlated with high 245 symptom severity at follow-up 1 and 2 and low serum PO4 levels were linked to reduced social 246 functioning and increased gastrointestinal complaints at follow-up 2. Surprisingly, in PCS patients, 247 high IL-8 levels at baseline correlated with high total symptom scores (qCCC) at follow-up 2 but 248 improved physical functioning and less physical fatigue (CFQ) at follow-up 1. Likewise, reduced serum 249 PO4 was associated with low total symptom scores (qCCC) at follow-up 1 while at follow-up 2 (in line 250 with PCS-ME/CFS) the link was to decreased health perception and health change. High MBL levels 251 were associated with less fatigue symptoms (CFQ) at follow-up 2.

252

253

254 Discussion

We here provide a comprehensive longitudinal characterization of the post-COVID-19 condition in patients with pronounced fatigue and exertion intolerance over a period of 20 months following COVID-19. All patients suffered from PCS, with a subgroup fulfilling the CCC for ME/CFS.

258 While both PCS and PCS-ME/CFS patients continued to report post-COVID-19 symptoms throughout 259 the observation period^{26,27}, clinical improvement was observed to variable degrees and mostly

restricted to the non-ME/CFS sub-cohort. This is in line with Tran et al. (37) who monitored symptom evolution in patients with persisting symptoms after acute COVID-19 based on an online survey over a 12-month period. The proportion of patients with persisting symptoms in their cohort was about 85%. After an initial decrease, symptoms plateaued 6 to 8 months after onset.⁸ Consistently, Seeßle et al. (38) reported that neurocognitive deficits following COVID-19 can persist beyond 12 months and lead to a marked reduction of quality of life. ²⁸

266 We here showed that patients fulfilling criteria for ME/CFS continued to be more affected than PCS 267 patients by a wide range of symptoms including fatigue, physical disability, impaired social 268 functioning, and emotional well-being. Importantly, exertion intolerance and PEM as the hallmark of 269 post-infectious fatigue syndromes remained more pronounced in PCS-ME/CFS up to 20 months after 270 initial infection. However, the extent of PEM did not improve in either cohort. Considering this 271 persistence of PEM in most PCS patients, our study provides evidence that in ME/CFS, despite early 272 diagnosis, prognosis is poor for most patients. Accordingly, its management by determining 273 individual activity limits and balancing rest and activity (i.e., pacing) gains in importance. All patients 274 in this study were seen in our specialist outpatient clinics and received recommendations for 275 symptomatic treatment and self-management strategies. However, symptomatic therapy in ME/CFS 276 requires prompt clinical follow-ups, which have not been available for most patients due to a lack of knowledge among most primary physicians.²⁹ We are currently evaluating in a clinical trial if 277 278 comprehensive care and close monitoring can improve physical function and well-being in ME/CFS 279 patients.

280 The degree of fatigue and functional disability as evaluated by Chalder and Bell scales and hand grip 281 strength and fatiguability were found to discriminate best between PCS and PCS-ME/CFS patients 16 282 to 20 months post infection. POTS was found only in PCS-ME/CFS patients at a prevalence of 6% 283 consistent with other reports. Given these characteristic features and distinct disease course of the 284 PCS-ME/CFS sub-group, classification of patients with the post-COVID condition based on the CCC is 285 useful for further diagnostics and treatment. 16 of the 51 PCS patients not fulfilling the CCC would 286 have fulfilled the IOM (Institute of Medicine) criteria for ME/CFS as these criteria do not predefine 287 the length of PEM and require only fatigue, sleep disturbance and cognitive or orthostatic symptoms 288 as mandatory symptoms. In line with other studies, patients fulfilling the CCC were more impaired 289 and more symptomatic.³⁰

The majority of patients reported newly emerged affective symptoms and poor emotional well-being after COVID-19 diagnosis, which were thus directly related to their post-COVID-19 condition. These symptoms improved only in PCS patients along with their overall clinical condition and therefore

293 must rather be considered a consequence of the burdening disease impacting PCS-ME/CFS patients'

quality of life. Consequently, psychological support should be integrated into PCS management.

295 We found baseline HGS to be linked to persisting disease severity, particularly in the PCS-ME/CFS 296 cohort. PCS-ME/CFS patients with initially reduced HGS were more likely to experience high disease 297 burden up to 20 months after infection. Specifically, higher hand grip force correlated with a lower 298 amount of fatigue, exertion intolerance, physical functioning and disability, the characteristic 299 hallmarks of chronic postinfectious fatigue syndromes. In PCS patients, links of HGS to these 300 symptom measures were not found or were much less pronounced than in PCS-ME/CFS. We thus 301 assume that HGS is a more valuable prognostic parameter for patients with PCS-ME/CFS. 302 Consequently, HGS measurements could serve as an easy to perform method to estimate prognosis 303 of PCS-ME/CFS patients. However, these correlations should be considered observational as we could 304 not control for potential confounding variables due to the limited number of participants. Therefore, 305 these results need to be validated in further studies.

We observed a distinct improvement of symptoms (fatigue, PEM, and disability) in 7 out of 55 PCS-ME/CFS patients. These patients initially presented with severe symptoms and fulfilled the Canadian Consensus diagnostic criteria for ME/CFS. At follow-up 2, their Bell scores were improved above a value of 60 points. 5 of them also demonstrated improved hand grip strength over time. We were unable to identify common characteristics that could explain this improvement in this sub-group.

311 Our evaluation of biomarkers associated with post-infectious fatigue supports the presumption of 312 ongoing inflammation in post COVID-19. The pro-inflammatory, neutrophil-recruiting cytokine IL-8 313 and ferritin were elevated in a subgroup of patients 6 months after infection. IL-8 levels decreased 314 towards 12 months after SARS-CoV-2 infection. Further, we observed elevated ANA titers in 25% of 315 patients. This is consistent with other studies that found elevated ANA titers at 12 months post-316 COVID, which correlated with persisting symptoms and inflammation in PCS patients. This indicates that ANA could be a relevant marker for autoimmunity in PCS.³¹ Hypophosphatemia was found in 317 318 one third of patients at baseline and interestingly persisted only in the ME/CFS cohort. The etiology 319 of hypophosphatemia is complex and potential causes are mitochondrial dysfunction with depletion of adenosine triphosphate (ATP), insulin resistance, and respiratory alkalosis.²⁴ Complications of 320 321 hypophosphatemia include impaired cellular ATP metabolism and increased affinity of hemoglobin to 322 oxygen in red blood cells, which may exacerbate fatigue as well as neurologic, cardiovascular and 323 muscle dysfunction. Thus, the effect of phosphate supplementation should be evaluated in ME/CFS. In acute COVID, results on supplementation approaches are still inconsistent.³² 324

A limitation of this study is the participant drop-out during the study period. Approximately 78% of dropouts were diagnosed with PCS at baseline, the remaining dropouts with PCS-ME/CFS. As PCS

patients were overall more likely to experience clinical improvement, they may have regarded further participation in the study as unbeneficial. Hence, their clinical improvement during follow-up could not be documented, which may bias the PCS cohort towards the more affected individuals. However, a great strength of this study is the comprehensive disease evaluation including an extensive and interdisciplinary set-up of questionnaires and on-site clinical examinations and functional and laboratory tests. Furthermore, more clinically less affected PCS patients would have only emphasized the discriminatory effect observed between our two patient groups.

Taken together, the post-COVID-19 condition may develop into a chronic syndrome with long-lasting symptoms and impairment. In patients fulfilling the CCC, the chance of relevant improvement by symptomatic therapy is low. Against the backdrop of over 675 million documented SARS-CoV-2 infections worldwide (status February 2023), these results suggest that the post-COVID-19 syndrome continues to present a heavy burden for those affected as well as on healthcare systems. Further studies on the pathomechanism and therapy approaches are urgently needed.

340

341 Methods

342 Study design and cohort characteristics

343 This work's data was collected as part of the Pa-COVID study of the Charité – Universitätsmedizin 344 Berlin and approved by the ethics committee of the Charité in accordance with the 1964 Declaration 345 of Helsinki and its later amendments (EA2/006/20). The current manuscript analyses follow-up data from a prospective observational cohort study of patients with severe fatigue and exertion 346 intolerance post COVID-19 diagnosis.³³ Patients were recruited via the Charité's Fatigue outpatient 347 348 clinic's website and the post-COVID consultation of the outpatient clinic of Charité's Experimental 349 and Clinical Resarch Center. From a total of 250 patients who were seen between July 2020 and 350 February 2022, 171 fulfilled the inclusion criteria of (Supp. Fig. 1a): (1) confirmed previous diagnosis 351 of mild to moderate COVID-19 according to WHO criteria I or II, (2) persistent moderate to severe 352 fatigue according to the CFQ and PEM, (3) absence of COVID-19-related organ dysfunction in case of 353 indicative symptoms and 4) absence of preexisting fatigue or relevant cardiac, respiratory, neurological, or psychiatric comorbidities according to the European Network on ME/CFS 354 355 (EUROMENE) guidelines.¹⁰ COVID-19 diagnose was confirmed by SARS-CoV-2 polymerase chain 356 reaction or anti-SARS-CoV-2 IgG serology (only prior to vaccination). To exclude COVID-19-related 357 organ dysfunction, patients with severe headache or cognitive impairment were evaluated by a 358 neurologist, patients with respiratory problems underwent comprehensive pulmonological 359 examination including chest computer tomography and pulmonary function tests with diffusing 360 capacity and patients with chest pain, postural tachycardia, palpitations, or elevated NT-pro BNP had

361 a cardiological examination and were assessed by electrocardiogram (ECG), 24h ECG and 362 echocardiography. Baseline assessment was conducted 3 to 8 months post COVID-19 manifestation. 363 Follow-up visits were scheduled 9 to 16 months (follow-up 1) and 17 to 20 months (follow-up 2) post 364 COVID-19 diagnosis (see Supp. Fig. 1b). All visits included questionnaires as well as functional and 365 laboratory tests (see Supp. Fig. 1b). An additional questionnaire-based assessment was conducted 9 366 months post COVID-19 to standardize diagnoses of patients with baseline visits at months 3 and 4 367 post infection as ME/CFS can only be diagnosed after symptom persistence of more than 6 months. 368 These assessments were not used for analysis. 65 patients (n=51 PCS, n=14 PCS-ME/CFS) dropped 369 out during the study resulting in 106 patients with complete datasets from at least two different 370 assessments timepoints (baseline and one follow-up).

371

372 Diagnosis and symptom assessment

PCS was diagnosed based on fatigue, PEM and, optionally, additional key symptoms following COVID-19 persisting for at least 3 months and impairing daily live according to the WHO "clinical case definition of post-COVID-19 condition".⁴ The diagnosis of PCS-ME/CFS was based on the CCC and PEM lasting until the next day. The minimum PEM duration required for diagnosis was set at 14 hours as this cut-off value has been shown to be reliable in distinguishing ME/CFS fatigue from fatigue associated with other diseases.³⁴ In contrary, patients with PCS did not fulfill all CCC criteria and most presented with PEM less than 14 hours.

380 Post-COVID-19 cardinal symptoms and their severity were assessed (on a scale from 1-10, no symptoms to extreme symptoms) using the qCCC (2003).³⁵ Symptom complexes were summed up 381 382 respectively: Fatigue, impaired performance, need for rest and post exertional malaise were 383 summarized as gCCC fatigue score. Painful lymph nodes, sore throat and flu-like symptoms were 384 summed up as qCCC immune score. Concentration impairment, memory/wordfinding problems and 385 mental fatigue were summerzied as gCCC mental score. The CFQ is a broadly recognized measuring 386 tool for the diagnosis of ME/CFS fatigue and contains 11 items on an ordinal scale of 0 to 3 with a 387 minimal total score of 0 (no fatigue) to a maximum total score of 33 (strong fatigue).^{36,37} The two 388 subscales are rated as follows: mental fatigue (CFQA) contains 4 items with a range of 0 to 12 and 389 physical fatigue (CFQB) 7 items with a range of 0 to 21. Frequency, severity and duration of PEM 390 symptoms were assessed according to Cotler et al. (range 0 to 46, no PEM to frequent, severe or long-lasting PEM).³⁴ Impairment in daily life due to chronic fatigue was rated based on the Bell 391 392 disability scale with increasing impairment from 100 (no symptoms present) to 50 (moderate 393 symptoms at rest and moderate to severe symptoms with exercise or activity; unable to perform 394 strenuous duties, but able to perform light duty or desk work 4-5 hours a day) and 0 points (unable

to get out of bed independently).³⁸ Physical and social dysfunction, bodily pain, emotional well-being, 395 396 general health perception and health change were evaluated by the SF-36, which is used as a generic 397 measurement tool to assess health perception, disease progression and experienced impairment through illness.³⁹ Its score ranges from 0 (greatest possible health limitation) to 100 (no relevant 398 health limitation) points. The subitems orthostatic intolerance and gastrointestinal function of the 399 400 COMPASS 31 were used to detect symptoms of autonomic dysfunction often reported by PCS 401 patients with a minimum total score of 0 (no symptoms) and a maximum total score of 100 (strong autonomic dysfunction).⁴⁰ Furthermore, we used the PHQ9, a guestionnaire to screen for depressive 402 symptoms²⁶: Due to the overlap of several PCS symptoms with depressive disorders, the PHQ9 score 403 404 was used descriptively only.

405

406 Functional tests and biomarker assessment

407 POTS, OH and diminished HGS were used as clinical markers to comprehensively characterize the 408 broad variety of symptoms and their severity seen in PCS patients. POTS and OH describe different phenotypes of autonomic dysfunction and are often seen in ME/CFS patients.⁴¹⁻⁴³ For evaluation. 409 410 blood pressure and heart rate were measured in seated position, immediately after standing up and 411 after 2, 5 and 10 minutes (standing). Orthostatic intolerance was defined as increase of more than 30 bpm or above 120 bpm within 10 minutes after standing up.^{43,44} OH was defined as decrease of 412 413 systolic pressure of more than 20 mmHg or diastolic pressure of more than 10 mmHg at any measurement.⁴³ HGS, which is a meaningful marker for evaluation of muscle exertion and fatigability 414 in fatigue patients, was assessed using an electronic dynamometer.²⁵ In detail, patients gripped the 415 416 measuring device 10 times with maximum force with their leading hand. This procedure was 417 repeated after 60 minutes. Maximum (fmax1, fmax2) and mean (fmean1, fmean 2) force of each 418 session were determined in kg. Previous studies by Jäkel et al. identified reference values in healthy females (fmean1=25.6; fmean2=25.9; fmax1=28.2; fmax2=28.7) and determined cut-off values for 419 the diagnosis of ME/CFS in patients 20-39 years and 40-59 years respectively.²⁵ Furthermore, we 420 421 calculated the fatigue ratio as correlates of decreased force after repeated measurements and the recovery ratio indicating lower force during the second measurement.²⁵ We decided to investigate 422 423 multiple laboratory parameters, which have previously been associated with postinfectious fatigue 424 syndromes including ferritin (reference range 13-150 µg/l), IL-8 in erythrocytes (reference <150 pg/ml), MBL (reference >50 ng/ml), ANAs (reference negative 1:0 dilution) and PO4 (reference range 425 0.87-1.45 mmol/l).⁴⁵ They were determined at the Charité diagnostics laboratory (Labor Berlin 426 GmbH, Berlin, Germany). 427

428 Statistical analysis

429 Study data were collected and managed using REDCap, an electronic data collection system, and last 430 accessed on December 13, 2022. Non-parametric rank-based ANOVA tests for factorial longitudinal 431 data were used for data analysis. These tests are a generalization of the Wilcoxon-Mann-Whitney 432 test for longitudinal data. We tested for group effects, time effects, and an interaction effect 433 between these two effects. A group effect corresponds to a significant difference in the distribution 434 of data between the PCS and the PCS-ME/CFS cohort, a time effect to a significant change in the data 435 distribution over time, and an interaction effect to a temporal trend difference between the PCS and 436 the PCS-ME/CFS cohort. Note that the reported effect sizes are relative (i.e., the probability of 437 observing larger values for a given group at a given time). In a subsequent post-hoc analysis, 438 Wilcoxon-Mann-Whitney tests were used to analyze group differences at individual time periods. The 439 corresponding p-values were adjusted according to the Holm-Bonferroni correction. Correlation 440 analyses were performed using Kendall's Tau correlation. In general, p-values < 0.05 were considered 441 statistically significant. Statistical testing was done in Prism version 9 and R version 4.2.1 with the 442 packages tidyverse version 1.3 and nparLD version 2.2.

443

444 References

1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med*.
2021;27(4):601-615. doi:10.1038/s41591-021-01283-z

447 2. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised
448 patients with COVID-19: a longitudinal prospective cohort study. *The Lancet Regional Health* 449 *Europe*. 2021;6:100122. doi:10.1016/j.lanepe.2021.100122

450 3. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med*.
451 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y

Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19
 condition by a Delphi consensus. *The Lancet Infectious Diseases*. Published online December
 2021:S1473309921007039. doi:10.1016/S1473-3099(21)00703-9

4555.Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and456management. BMJ. Published online July 26, 2021:n1648. doi:10.1136/bmj.n1648

457 6. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7
458 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.
459 doi:10.1016/j.eclinm.2021.101019

460 7. Goërtz YMJ, Herck MV, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-

461 CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Research*. 2020;6(4).

462 doi:10.1183/23120541.00542-2020

463 8. Tran VT, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time

in the ComPaRe long COVID prospective e-cohort. *Nat Commun*. 2022;13(1):1812.

465 doi:10.1038/s41467-022-29513-z

466 9. Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 467 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated 468 with symptom severity. Nat Commun. 2022;13(1):5104. doi:10.1038/s41467-022-32507-6 469 Nacul L, Authier FJ, Scheibenbogen C, et al. European Network on Myalgic 10. 470 Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, 471 Service Provision, and Care of People with ME/CFS in Europe. *Medicina*. 2021;57(5):510. 472 doi:10.3390/medicina57050510 473 Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: 11. 474 International Consensus Criteria. J Intern Med. 2011;270(4):327-338. doi:10.1111/j.1365-2796.2011.02428.x 475 476 Jason LA, Sunnquist M, Brown A, Reed J. Defining Essential Features of Myalgic 12. 477 Encephalomyelitis and Chronic Fatigue Syndrome. Journal of Human Behavior in the Social 478 Environment. 2015;25(6):657-674. doi:10.1080/10911359.2015.1011256 479 13. Sotzny F, Blanco J, Capelli E, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – 480 Evidence for an autoimmune disease. Autoimmunity Reviews. 2018;17(6):601-609. 481 doi:10.1016/j.autrev.2018.01.009 482 14. Loebel M, Grabowski P, Heidecke H, et al. Antibodies to β adrenergic and muscarinic 483 cholinergic receptors in patients with Chronic Fatigue Syndrome. *Brain, Behavior, and Immunity*. 484 2016;52:32-39. doi:10.1016/j.bbi.2015.09.013 485 15. Sotzny F, Filgueiras IS, Kedor C, et al. Dysregulated autoantibodies targeting vaso- and 486 immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front 487 Immunol. 2022;13:981532. doi:10.3389/fimmu.2022.981532 488 16. Brodin P, Casari G, Townsend L, et al. Studying severe long COVID to understand post-489 infectious disorders beyond COVID-19. Nat Med. Published online April 5, 2022:1-4. 490 doi:10.1038/s41591-022-01766-7 491 17. Haffke M, Freitag H, Rudolf G, et al. Endothelial dysfunction and altered endothelial 492 biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J 493 Transl Med. 2022;20(1):138. doi:10.1186/s12967-022-03346-2 494 Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. 18. 495 Cell. 2022;185(5):881-895.e20. doi:10.1016/j.cell.2022.01.014 496 19. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent Circulating Severe Acute Respiratory 497 Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. 498 Clinical Infectious Diseases. 2023;76(3):e487-e490. doi:10.1093/cid/ciac722 499 Son K. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID 20. 500 symptoms.:37. 501 Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 21. 502 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210-216. 503 doi:10.1038/s41590-021-01113-x 504 22. Pasini E, Corsetti G, Romano C, et al. Serum Metabolic Profile in Patients With Long-Covid 505 (PASC) Syndrome: Clinical Implications. Frontiers in Medicine. 2021;8. Accessed November 2, 2022. 506 https://www.frontiersin.org/articles/10.3389/fmed.2021.714426

507 23. Reinsberg J, Dembinski J, Dorn C, Behrendt D, Bartmann P, van Der Ven H. Determination of 508 total interleukin-8 in whole blood after cell lysis. Clin Chem. 2000;46(9):1387-1394.

509 24. Wang R, He M, Kang Y. Hypophosphatemia at Admission is Associated with Increased 510 Mortality in COVID-19 Patients. Int J Gen Med. 2021;14:5313-5322. doi:10.2147/IJGM.S319717

511 25. Jäkel B, Kedor C, Grabowski P, et al. Hand grip strength and fatigability: correlation with 512 clinical parameters and diagnostic suitability in ME/CFS. Journal of Translational Medicine.

513 2021;19(1):159. doi:10.1186/s12967-021-02774-w

514 26. Gräfe K, Zipfel S, Herzog W, Löwe B. Screening psychischer Störungen mit dem

515 "Gesundheitsfragebogen für Patienten (PHQ-D)": Ergebnisse der deutschen Validierungsstudie.

516 [Screening for psychiatric disorders with the Patient Health Questionnaire (PHQ). Results from the

517 German validation study.]. Diagnostica. 2004;50(4):171-181. doi:10.1026/0012-1924.50.4.171

518 27. Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, Wessely SC. Population based 519 study of fatigue and psychological distress. BMJ. 1994;308(6931):763-766.

520 doi:10.1136/bmj.308.6931.763

521 28. Seeßle J, Waterboer T, Hippchen T, et al. Persistent Symptoms in Adult Patients 1 Year After 522 Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis. 2022;74(7):1191-523 1198. doi:10.1093/cid/ciab611

524 29. Froehlich L, Hattesohl DBR, Jason LA, Scheibenbogen C, Behrends U, Thoma M. Medical Care 525 Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Germany. Medicina 526 (Kaunas). 2021;57(7):646. doi:10.3390/medicina57070646

527 30. Jason LA, McManimen S, Sunnquist M, Newton JL, Strand EB. Clinical Criteria Versus a 528 Possible Research Case Definition in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Fatigue. 529 2017;5(2):89-102. doi:10.1080/21641846.2017.1299077

530 31. Son K, Jamil R, Chowdhury A, et al. Circulating anti-nuclear autoantibodies in COVID-19 531 survivors predict long COVID symptoms. European Respiratory Journal. 2023;61(1). 532 doi:10.1183/13993003.00970-2022

533 32. Fakhrolmobasheri M, Vakhshoori M, Heidarpour M, Najimi A, Mozafari AM, Rezvanian H. 534 Hypophosphatemia in Coronavirus Disease 2019 (COVID-19), Complications, and Considerations: A 535 Systematic Review. Biomed Res Int. 2022;2022:1468786. doi:10.1155/2022/1468786

536 Kedor C, Freitag H, Meyer-Arndt L, et al. Chronic COVID-19 Syndrome and Chronic Fatigue 33. 537 Syndrome (ME/CFS) Following the First Pandemic Wave in Germany – a First Analysis of a Prospective 538 Observational Study. Infectious Diseases (except HIV/AIDS); 2021. doi:10.1101/2021.02.06.21249256

539 34. Cotler J, Holtzman C, Dudun C, Jason LA. A Brief Questionnaire to Assess Post-Exertional 540 Malaise. Diagnostics (Basel). 2018;8(3):66. doi:10.3390/diagnostics8030066

541 Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic Encephalomyelitis/Chronic Fatigue 35. 542 Syndrome. Journal of Chronic Fatigue Syndrome. 2003;11(1):7-115. doi:10.1300/J092v11n01 02

543 Jackson C. The Chalder Fatigue Scale (CFQ 11). Occupational Medicine. 2015;65(1):86. 36. 544 doi:10.1093/occmed/kqu168

545 37. Morriss R, Wearden A, Mullis R. Exploring the validity of the chalder fatigue scale in chronic 546 fatigue syndrome. Journal of Psychosomatic Research. 1998;45(5):411-417. doi:10.1016/S0022-

3999(98)00022-1 547

548 38. Bell DS. *The Doctor's Guide to Chronic Fatigue Syndrome Understanding, Treating, and Living* 549 *with CFIDS*. Addison-Wesley; 1995.

55039.Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual551framework and item selection. *Med Care*. 1992;30(6):473-483.

- 552 40. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: A Refined and
- 553 Abbreviated Composite Autonomic Symptom Score. *Mayo Clin Proc*. 2012;87(12):1196-1201.
- 554 doi:10.1016/j.mayocp.2012.10.013
- 555 41. Hoad A, Spickett G, Elliott J, Newton J. Postural orthostatic tachycardia syndrome is an under-
- recognized condition in chronic fatigue syndrome. *QJM*. 2008;101(12):961-965.
- 557 doi:10.1093/qjmed/hcn123
- Shanks L, Jason LA, Evans M, Brown A. Cognitive impairments associated with CFS and POTS.
 Front Physiol. 2013;4:113. doi:10.3389/fphys.2013.00113
- 560 43. Natelson BH, Lin JMS, Blate M, Khan S, Chen Y, Unger ER. Physiological assessment of
- orthostatic intolerance in chronic fatigue syndrome. *J Transl Med*. 2022;20(1):95.
- 562 doi:10.1186/s12967-022-03289-8

563 44. Haensch CA, Wagner C, Mallien J, Isenmann S. Posturales Tachykardiesyndrom.

- 564 *Nervenheilkunde*. 2013;32(4):199-204. doi:10.1055/s-0038-1628499
- 565 45. Son K, Jamil R, Chowdhury A, et al. Circulating anti-nuclear autoantibodies in COVID-19
- survivors predict long-COVID symptoms. *European Respiratory Journal*. Published online January 1,
 2022. doi:10.1183/13993003.00970-2022

568

569 Acknowledgements

We thank Elena Steinle, Gritt Stoffels and Anja Hagemann for patient care and data management.
We thank all patients who gave us their consent to publish their data in this study. We thank all
members of the PaCOVID-19 collaborative study group.

573

574 Funding

575 This work is supported by a grant from the Weidenhammer-Zoebele Foundation. The work of F. K. 576 was supported by the Volkswagen Foundation.

577

578 Data availability

579 Data is available upon reasonable request. Furthermore, the manuscript's guarantor affirms that the 580 paper is honest, accurate, and transparent; that no important aspects of the study have been 581 omitted; and that any discrepancies from the study as planned have been explained. Dissemination 582 to participants and related patient and public communities is encouraged by open access publication 583 and citing the study on our site <u>https://cfs.charite.de/</u>. We are engaging with print and internet 584 press, television, radio, news, and documentary program makers. All items of the STROBE checklist 585 are covered in the paper.

586

587 Author Contributions

588 C.S, C.K., and F.P. developed the concept of the study. L.M.-A. gave important input into study 589 concept and objectives. A.F.K. and L.M.-A. were responsible for data curation and analyses of data. 590 C.K., U.H., C.S., J.B.-S., L.M.-A., F.P. were involved in clinical investigation. A.F.L was involved in data 591 transfer, data management and collection of further information for revision. H.F. was also involved 592 in data transfer. C.K., J.B.-S. and C.S. validated the data. L.M. performed statistical analyses. A.F.L and 593 L.M. were involved in data visualization. A.F.L and L.M.-A wrote the original draft of the paper. C.S. 594 and J.B.-S. reviewed and edited the paper. All authors revised and approved the paper. The 595 corresponding author attests that all listed authors meet authorship criteria and that no others 596 meeting the criteria have been omitted. C.S. is the guarantor.

597

598 Competing Interest Statements

- 599 The authors declare no competing interests.
- 600

601 Figure legends

602Fig. 1: Fatigue. a, Chalder Fatigue Total Score, ranging from 0 (no fatigue) to 33 (severe fatigue); b, Chalder Fatigue Physical603Score (range 0-21); c, SF-36 Energy/Fatigue, ranging from 0 (most impaired) to 100 (no impairment); d, Chalder Fatigue604Mental Score (range 0-12). Dots represent absolute score values (red for PCS, blue for PCS-ME/CFS) as quantified on the left605Y axis. Bars depict group medians. Lines (red for PCS, blue for PCS-ME/CFS) depict main relative time, group, and interaction606effects as quantified on the right Y axis. $p \le 0.05 = *, p \le 0.01 = ***, p \le 0.001 = ***. p \le 0.001 = ****.$

607Fig. 2: PEM. a, PEM duration (in hours), b, frequency (stated as occurring: never, rarely, half of the time, most of the time,608always), and c, severity (stated as: not at all, mild, moderate, severe, very severe) of exhaustion experienced post exertion.609Dots represent absolute score values (red for PCS, blue for PCS-ME/CFS) as quantified on the left Y axis. Bars depict group610medians. Lines (red for PCS, blue for PCS-ME/CFS) depict main relative time, group and interaction effects as quantified on611the right Y axis. $p \le 0.05 = *, p \le 0.01 = ***, p \le 0.001 = ***, p \le 0.0001 = ****.$

Fig. 3: General health and functional impairment. a, Bell score assessing disability due to chronic fatigue from 100 (no symptoms present) to 50 (moderate symptoms at rest and moderate to severe symptoms with exercise or activity) to 0 points (unable to get out of bed independently); b, SF-36 social functioning; **c,** SF-36 physical functioning; **d,** SF-36 health perception, 0 points (greatest possible health limitation) - 100 points (no health limitation). Dots represent absolute score values (red for PCS, blue for PCS-ME/CFS) as quantified on the left Y axis. Bars depict group medians. Lines (red for PCS, blue for PCS-ME/CFS) depict main relative time, group, and interaction effects as quantified on the right Y axis. $p \le 0.05 = *, p \le$ $0.01=**, p \le 0.001=***, p \le 0.0001=****$.

619Fig. 4: Emotional impairment. a, SF-36 emotional well-being, 0 points (greatest possible health limitation) - 100 points (no620health limitation); b, Patient Health Questionnaire 9 (PHQ9), minimal depressive symptoms (1-4), mild depressive621symptoms (5-9), moderate depressive symptoms (10-14), moderately severe depressive symptoms (15-19), or severe622depressive symptoms (20-27). Dots represent absolute score values (red for PCS, blue for PCS-ME/CFS) as quantified on the623left Y axis. Bars depict group medians. Lines (red for PCS, blue for PCS-ME/CFS) depict main relative time, group, and624interaction effects as quantified on the right Y axis. $p \le 0.05 = *$, $p \le 0.001 = ***$, $p \le 0.0001 = ****$.

625Fig. 5: Pain and autonomic dysfunction. a, SF-36 pain score, 0 points (greatest possible health limitation) - 100 points (no626health limitation); b, COMPASS 31 overall score, 0 (no symptoms) - 100 (severe autonomic dysfunction); c, COMPASS 31627gastrointestinal score (range 0-25). Dots represent absolute score values (red for PCS, blue for PCS-ME/CFS) as quantified628on the left Y axis. Bars depict group medians. Lines (red for PCS, blue for PCS-ME/CFS) depict main relative time, group, and629interaction effects as quantified on the right Y axis. $p \le 0.05 = *$, $p \le 0.001 = ***$, $p \le 0.0001 = ****$.

Fig. 6: Hand grip strength. a-d, mean (a and b) and maximum (c and d) force in kg of all 10 measurements per session for session 1 (a and c) and 2 (b and d) for baseline and follow-up 1; e and f, fatigue ratio (fmax/fmean) per session for session 1 (e) and 2 (f) and for baseline and follow-up 1; g, recovery ratio (fmean2/fmean1) for baseline and follow-up 1. Triangle data points depict patients <40 years. Age-dependent cut-offs are depicted according to Jäkel et al.²⁹ Red dots represent PCS cohort, white dots PCS-ME/CFS cohort. Bars depict group medians with a 95% confidence interval. $p \le 0.05 = *, p \le 0.01 = ***$, $p \le 0.001 = ****, p \le 0.0001 = ****$. Abbreviations: BL = baseline, FU1 = follow-up 1, se_1 = session 1, se_2 = session 2.

Fig. 7: Inflammatory biomarkers associated with postinfectious fatigue. a) interleukin 8 (IL-8) after erylysis, reference <150 pg/ml, b, ferritin, reference range 13-150 µg/l, c, antinuclear antibodies (ANA), negative reference 1:0 dilution, d, serum phosphate (PO4), reference range 0.87-1.45 mmol/l, for baseline and follow-up 1 respectively. Dots represent absolute score values (red for PCS, blue for PCS-ME/CFS) as quantified on the left Y axis. Bars depict group medians. Lines (red for PCS, blue for PCS-ME/CFS) depict main relative time, group, and interaction effects as quantified on the right Y axis. $p \le 0.05 = *, p \le 0.01 = **, p \le 0.001 = ***$.

642 Fig. 8: Correlations of initial symptom severity, HGS and biomarkers with longitudinal symptom severity in a, PCS-ME/CFS

643patients and b, PCS patients. Markers at baseline are shown on the x axis, parameters at follow-up 1 and 2 on the y axis.644Blue coloring indicates negative correlations, red coloring indicates positive correlations, see color legend below the plot; p645 $\leq 0.05 = *, p \leq 0.01 = **, p \leq 0.001 = ***, p \leq 0.0001 = ****.$

646

647 Tables

	<u>PCS (n=51)</u>		PCS-ME/C	FS (n=55)	<u>Total (n=106)</u>			
	Median	Range	Median	Range	Median	Range		
Sex (m/f)	15/36		6/49		21/85			
Age	43	19-66	43	20-62	40	19-66		
BMI	25	18-40	24	15-35	24	15-40		

648 Table 1

Table 1: Demographic participant characteristics. Median and range are reported for both cohorts separately as well as all
 participants together.

	Baseline					Follow-up 1 Follow-up 2											
Considion Conservation				P-value	D.05 D.05 N.15 (05 S			P-value					P-value		B 00 050 (145		
Criteria quantified (CCCq)	Median	> %	Median	=/CFS %	groups	Median	> %	Mediar	E/CFS	groups	Mediar		Mediar	1E/CFS	groups	effect*	PCS-CFS/IVIE time effect*
Fatigue	7	100	8	100	0.18	6	98	8	100	< 0.01	5	100	8	100	< 0.01	<0.01	0.58
PEM	7	88	8	100	< 0.01	6	98	8	100	< 0.01	5	96	8	98	< 0.01	<0.01	0.04
Need for rest	8	96	8	100	0.13	7	87	8	100	< 0.01	6	100	8	100	< 0.01	<0.01	0.51
Impaired performance	8	98	8	100	0.20	6	89	8	100	< 0.01	6	96	8	96	0.07	<0.01	0.18
Stress intolerance	8	94	8	98	< 0.01	7	97	8	100	< 0.01	6	100	8	98	< 0.01	0.04	0.97
Muscle pain	5	78	6	85	0.10	4	98	6	83	0.10	3	79	6	90	0.01	0.60	0.91
Headache	5	82	6	93	0.16	4	83	5	96	0.16	4	77.7	5	98	0.01	<0.01	0.19
Joint pain	4	69	5	64	0.29	2	63	5	77	0.29	3	59	5	65	0.29	0.75	0.75
Memory/word finding problems	5	88	5	98	0.72	5	91	5	91	0.91	3	83	6	88	0.15	<0.01	0.46
Concentration impairement	6	94	7	100	0.60	6	93	7	98	0.60	5	86	7	98	< 0.01	<0.01	0.62
Mental Fatigue	7	96	7	100	0.92	6	95	7	100	0.16	5	100	8	97	< 0.01	<0.01	0.86
Visual disturbance	3	66	3	67	1	2.5	71	3	64	1	2	69	2	66	0.90	0.81	0.81
Mood change	5	88.2	5	89	0.79	5	89	5	85	0.79	4	79	5	88	0.36	<0.01	0.73
Reading concentration	5	90	6	100	0.19	5	91	6	96	0.19	3	86	6	90	0.01	<0.01	0.81
Palpitations	3	65	3	89	0.08	2.5	74	5	85	0.07	3	76	5	80	0.04	0.49	0.49
Standing up dizziness	4	75	5	76	1	3	71	3	74	1	2	65	3	69	0.42	0.05	0.40
Walking dizziness	2	63	4	76	0.36	2	65	3	74	0.62	2	59	4	66	0.08	0.29	0.29
Sleep disturbance	7	86	7	91	1	6	82	6	89	1	5	76	7	90	< 0.01	<0.01	0.68
Temperature hypersensitivity	4	57	5	84	0.33	4	66	5	82	0.33	3	65	6	90	0.01	0.42	0.16
Light hypersensitivity	2	63	4	65	0.19	2	56	3	83	0.06	2	65	5	66	0.02	0.52	0.52
Noise hypersensitivity	5	73	6	91	0.27	6	76	6	94	0.41	4	96	7	90	0.06	0.43	0.55
Breathing difficulty	5	72.5	6	80	0.34	3	65	5	76	0.25	4	82	5	78	0.32	0.06	0.15
Irritable bowel	4	55	5	74	0.51	3	64	4	80	0.51	2	51.8	4	66	0.01	0.02	0.66
Fever	1	20	1	16	0.76	1	17	1	25	0.66	1	10	1	23	0.47	0.50	0.50
Painful lymph nodes	1	30	1	27	1	1	20	1	28	1	1	14	1	42	0.04	0.18	0.18
Sore throat	2	55	2	62	0.50	1	39	3	62	0.13	1	31	3	68	< 0.01	0.01	0.29
Flu-like symptoms	4	74.5	6	83	0.04	2	52	5	71	< 0.01	1.5	50	5	85	< 0.01	<0.01	0.30
Symptom severity	7	88.2	8	91	0.02	6	97	7	100	0.01	5	100	7	100	< 0.01	<0.01	0.29

651 Table 2

652 Table 2: Frequency (in %) and severity (median scores) of symptoms as quantified by the Canadian Consensus Criteria

(qCCC) for all three time periods. Group differences are reported as p-values and significant results (< 0.05) are marked in
 bold.

655

A Chalder Total Score



B Chalder Physical Score



C SF-36 Energy/Fatigue



D Chalder Mental Score



A **PEM Duration**



B PEM Frequency



C PEM Severity



A Bell Total Score



B SF-36 Social functioning



C SF-36 Physical functioning



D SF-36 Health perception



PCS PCS-ME/CFS

A SF-36 Emotional well-being



В

PHQ9 Affective symptoms

PCS PCS-ME/CFS

A SF-36 Pain Score



C COMPASS 31 Gastrointestinal Score



B COMPASS 31 Overall Score

•





G HGS Recovery Ratio





Α Interleukin-8 after erylysis



В Ferritin



С

1:1000

1:640

1:500

1:320

1:160

1:0

33 (51)

Dilution



D Serum phosphate



PCS-ME/CFS • PCS

Figure 8 A

Correlations PCS-ME/CFS Cohort



Baseline



Figure 8 B

Correlations PCS Cohort



